PMID- 23627853
OWN - NLM
STAT- PubMed-not-MEDLINE
DCOM- 20131104
LR  - 20211021
IS  - 1744-8336 (Electronic)
IS  - 1478-7210 (Linking)
VI  - 11
IP  - 5
DP  - 2013 May
TI  - A novel mechanism of immune evasion mediated by Ebola virus soluble glycoprotein.
PG  - 475-8
LID - 10.1586/eri.13.30 [doi]
AB  - Ebola viruses encode two glycoproteins (GPs): a membrane-associated GP that is 
      present in the viral membrane and mediates viral attachment and entry into host 
      cells; and a secreted, nonstructural glycoprotein (sGP) that is identical to GP 
      over approximately 90% of its length. A recent study by Mohan and colleagues 
      attributes a novel immune evasion mechanism dubbed 'antigenic subversion' to sGP. 
      Using DNA immunization in mice, the authors demonstrate that sGP elicits 
      antibodies that crossreact with GP, but these antibodies are non-neutralizing. 
      Coimmunization with sGP plus GP or sequential immunizations with GP and sGP 
      direct the host antibody response toward non-neutralizing epitopes. Therefore, 
      the production of sGP may prevent effective neutralization of the virus during 
      Ebola virus infection, and may reduce the effectiveness of vaccines that rely 
      upon neutralizing antibody responses.
FAU - Basler, Christopher F
AU  - Basler CF
AD  - Department of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY 
      10029, USA. chris.basler@mssm.edu
LA  - eng
GR  - R01 AI059536/AI/NIAID NIH HHS/United States
PT  - Comment
PT  - Journal Article
PL  - England
TA  - Expert Rev Anti Infect Ther
JT  - Expert review of anti-infective therapy
JID - 101181284
CON - PLoS Pathog. 2012;8(12):e1003065. PMID: 23271969
EDAT- 2013/05/01 06:00
MHDA- 2013/05/01 06:01
CRDT- 2013/05/01 06:00
PHST- 2013/05/01 06:00 [entrez]
PHST- 2013/05/01 06:00 [pubmed]
PHST- 2013/05/01 06:01 [medline]
AID - 10.1586/eri.13.30 [doi]
PST - ppublish
SO  - Expert Rev Anti Infect Ther. 2013 May;11(5):475-8. doi: 10.1586/eri.13.30.